New combo therapy aims to shrink aggressive prostate cancer before surgery

NCT ID NCT03436654

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a mix of hormone-lowering medications (apalutamide, abiraterone, prednisone, and a GnRH drug) for a few months before surgery can shrink very high-risk prostate cancer and reduce the chance of it coming back. About 102 men with localized or low-volume metastatic prostate cancer are participating. The approach combines drugs, surgery, and possibly radiation to attack the cancer from multiple angles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Apalutamide, abiraterone acetate, prednisone, and GnRH agonist/antagonist
What this could lead to: If successful, this combination approach could significantly lower the chance of prostate cancer returning after treatment.
What could go wrong: This is a phase 2 trial with only 102 participants, so results are preliminary. The treatment involves multiple drugs and procedures, which may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States
Northwestern University

Evanston, Illinois, 60208, United States
University of Chicago

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.